Safety and immunogenicity of two octavalent pneumococcal conjugate vaccines in American Indian infants

Angelia Eick, Janné Croll, Robert Weatherholtz, Larry Croll, Mathuram Santosham

Research output: Contribution to journalArticlepeer-review

Abstract

We evaluated the safety and immunogenicity of two octavalent pneumococcal polysaccharide vaccines (serotypes 3, 4, 6B, 9V, 14, 18C, 19F, and 23F) conjugated to either diphtheria toxoid (PncD) or tetanus protein (PncT) among White Mountain Apache and Gila River Indian Community infants. This was a prospective, non-randomized, open label, comparative pilot study of PncD and PncT. Since this was a pilot study, a small sample size of 60 infants was enrolled. Enrolled healthy infants received either PncD or PncT at 2, 4, and 6 months of age. Antibody concentrations were measured by enzyme-immunoassay (EIA) prior to each dose and 1 month after the last dose. Local reaction rates were similar between PncD and PncT groups. The geometric mean concentrations (GMCs) were significantly higher for PncD than PncT for serotype 3 whereas GMCs were significantly higher for PncT for serotype 4. For this pilot study, both vaccines appeared to be safe and immunogenic in this group of American Indian infants.

Original languageEnglish (US)
Pages (from-to)1260-1264
Number of pages5
JournalVaccine
Volume22
Issue number9-10
DOIs
StatePublished - Mar 12 2004

Keywords

  • American Indian
  • Immunogenicity
  • Pneumococcal conjugate vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Safety and immunogenicity of two octavalent pneumococcal conjugate vaccines in American Indian infants'. Together they form a unique fingerprint.

Cite this